Enrollment Complete in Phase 3 MOMENTUM Myelofibrosis Trial

In late June, Sierra Oncology, Inc. announced it has completed enrollment of patients in the phase 3 MOMENTUM clinical trial. The trial is focused on evaluating treatment of patients with myelofibrosis who are symptomatic and anemic using a novel JAK1, JAK2 and ACVR1/ALK2 inhibitor called momelotinib.

Though Sierra Oncology, Inc. initially planned for 180 patients, there were 195 patients spanning across the globe enrolled in the randomized trial, which has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

“Oversubscribing the trial and completing enrollment at an accelerated pace in the midst of a global crisis supports our hypothesis that physicians want new options for a significant unmet need that momelotinib may address,” said Stephen Dilly, president and chief executive officer of Sierra Oncology, Inc. “We look forward to topline results early next year and to continue working with the FDA and global regulatory authorities to bring this therapy to market as quickly as possible."

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.